Article Sidebar
Published:
Oct 14, 2022Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Annexin A1 mimetic peptide Ac2-26 alleviates renal inflammatory injury in a diabetic mice model through the suppression of p38MAPK/NF-κB
Abstract
Purpose: To examine the protective effect of mimetic peptide Ac2-26 of Annexin A1 (ANXA1) against renal inflammatory injury in a diabetic mice model.
Methods: Twenty-four mice were randomized into three groups with eight mice per group. These included control group (CG), model group (MG) given intraperitoneal injection of streptozotocin (60 mg/kg), and AC2-26 group (AG) given AC2-26, 72 h after the induction of diabetes. Fasting blood glucose (FBG), blood lipids, and renal function in the mice were determined by Sysmex-180 Biochemistry Analyzer, while serum inflammatory factors in renal tissue were also determined.
Results: Compared with the model group, there was a significant decrease in the levels of FBG, triglyceride (TG), total cholesterol (TC), low-density lipoprotein (LDL), high-density lipoprotein (HDL), oxidized LDL (ox-LDL), as well as in 24 h urinary protein, creatinine (Cr) and blood urea nitrogen (BUN), but a significant increase in body weight in AC2-26 group (p < 0.001). There was a significant decrease in TNF-α, IL-6, IL-1β, and IL-18 levels, as well as in mRNA levels and protein expressions of p38MAPK, NF-κBP6, ANXA1 in AC2-26 group when compared with the model group (p < 0.001).
Conclusion: Annexin A1 is the target gene of p38MAPK. Annexin A1 mimetic peptide Ac2-26 alleviates renal inflammation by suppressing p38MAPK/NF-κB pathway, thus improving renal function in the diabetic mice model. Hence, the findings of this study provide a potential avenue for the development of an effective treatment for renal disease in diabetics.
